Cardiotoxicity caused by anthracyclines has long been a concern; however, unfortunately, patients still suffer from these complications. Most newly developed anticancer therapies in recent years have been molecular-targeted agents or immune checkpoint inhibitors. Although molecular-targeted drugs may induce cardiovascular complications such as cardiac dysfunction, QTc prolongation, venous thromboembolism, and peripheral arterial occlusion, immune checkpoint inhibitors carry the risk of causing severe myocarditis.

Advances in cancer treatment have improved patient outcomes, but cardiovascular complications remain an issue not only during treatment but also in cancer survivors. The number of patients with pre-existing cardiovascular diseases diagnosed with cancer is also on the rise. Therefore, cardiologists and oncology specialists must work closely together over the long term to ensure optimal care for these patients.

Promoting research and building a robust system of collaborative clinical care that ensures that cancer treatment can continue uninterrupted, even when complications arise, is imperative to prevent and manage cardiovascular complications arising from cancer therapies.

Furthermore, ethnic differences may influence the incidence and treatment responses of cardiovascular complications. Some medications proven effective overseas may not yield the same results in Japanese patients. Thus, it is crucial that we contribute data from Japan through clinical studies. I believe our society plays an important role in this effort.

Onco-cardiology has now begun to gain attention as a focus of national healthcare and is expected to significantly grow in the coming years. Our goal is to establish a nationwide system in which all cancer care hospitals can access onco-cardiology expertise. Through the advancement of this discipline, the Japanese Onco-Cardiology Society will strive to improve the quality of life and prognosis of patients with cancer.

We sincerely request your continued support and guidance.